Teng-Yi Huang, Ph.D., is a distinguished chemist specializing in carbohydrate chemistry and its applications in Antibody Drug Conjugate (ADC) platform development. Dr. Huang is the Director of Medicinal Chemistry and the Lead of GlycOBI™ ADC Platform at OBI Pharma. He leads research efforts aimed at developing innovative therapies, particularly, next-generation ADCs. Dr. Huang's leadership has propelled the company to the forefront of ADC platform development, making OBI a leader in the field. Dr. Huang obtained his Ph.D. in Chemistry from National Tsing Hua University in Taiwan. He was a postdoctoral research fellow at the Genomic Research Center, Academia Sinica, Taiwan.